SHR4640

Phase 1UNKNOWN

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Primary Gout

Conditions

Primary Gout, Hyperuricemia

Trial Timeline

Oct 1, 2020 → Dec 1, 2020

NCT ID

NCT04586803

About SHR4640

SHR4640 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Primary Gout. The current trial status is unknown. This product is registered under clinical trial identifier NCT04586803. Target conditions include Primary Gout, Hyperuricemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05954169	Phase 1	Completed	Aug 7, 2023	Jul 1, 2024	Hyperuricemia
NCT04620408	Phase 1	UNKNOWN	Dec 1, 2020	Feb 1, 2021	Healthy Subjects
NCT04586803	Phase 1	UNKNOWN	Oct 1, 2020	Dec 1, 2020	Primary Gout
NCT04305392	Phase 1	UNKNOWN	Aug 4, 2020	Dec 1, 2022	Hepatic Impairment

Competing Products

20 competing products in Primary Gout

See all competitors

Product	Company	Stage	Hype Score
Unfractionated heparin	Sinopharm	Pre-clinical	22
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
Latanoprost plus adjunctive glaucoma medication	Sight Sciences	Approved	77
REN001	OnKure Therapeutics	Phase 1	25
Mavodelpar + Placebo	OnKure Therapeutics	Phase 2	44
REN001	OnKure Therapeutics	Phase 2/3	57
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo	Skye Bioscience	Phase 2	44
Rituximab + Methotrexate + Cytarabine Injection	Celltrion	Phase 2	52
Rituximab, lenalidomide	Celltrion	Phase 2	52
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RIS	Chugai Pharmaceutical	Phase 3	77
CS-3150	Daiichi Sankyo	Pre-clinical	23
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Pre-clinical	23
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	85
Combination of bempedoic acid and ezetimibe	Daiichi Sankyo	Pre-clinical	23
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	77
Bempedoic acid and/or its fixed dose combination with ezetimibe	Daiichi Sankyo	Pre-clinical	23
Roxadustat + Placebo	Astellas Pharma	Phase 3	77
Enzalutamide + Exemestane	Astellas Pharma	Phase 2	52
Bocidelpar + Placebo	Astellas Pharma	Phase 2	52
Methotrexate + Ibrutinib + Temozolomide	Sun Pharmaceutical	Phase 2	52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved

Remimazolam TosilateApproved

Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved

ImrecoxibApproved

IvarmacitinibApproved